Non-inferiority of iPragliflozin and metformin on glucose metabolism, pleiotropic effects and safety in type2 diabetes

Trial Profile

Non-inferiority of iPragliflozin and metformin on glucose metabolism, pleiotropic effects and safety in type2 diabetes

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 May 2016

At a glance

  • Drugs Ipragliflozin (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Most Recent Events

    • 15 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top